Partner With Us NRI

Company details

6M Return -24.75%
1Y Return -6.57%
Mkt Cap.(Cr) 93.80
Volume 38,503
Div Yield 0.00%
OI Chg %
Volume 38,503

Open Free Demat Account Online with ICICIDIRECT


  • swot

  • technicals

  • deals

  • shareholding


Delivery and volume


  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio


Operating Profit(Cr.)

Profit after Tax(Cr.)


Reserves and Surplus



Operating Profit

Profit after tax





Equity Capital: 96.54 Cr FV: 10.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 1,077.60 36,508.33
LAST 3M 38,231.60 5,545.35
LAST 6M 121,291.29 -142,349.22
LAST 12M 212,636.06 -215,172.33


  • About Company
  • Company Info
  • Listing Info
  • Aarey Drugs & Pharmaceuticals Ltd is one of the manufacturer and suppliers of pharmaceutical raw materials, Chemicals, Pharmaceuticals ingredients, API`s Drugs, Food Colours and Flavours. The company is engaged in the business of manufacturing, selling of drugs & pharmaceutical products and is governed by a number of central and state legislations that regulate the business. Apart from the bulk drug manufacturing activity, they also undertake importing & distributing of various industrial chemicals & solvents throughout the country. The company has their manufacturing unit located at Thane. The company`s products include Methyl Nitro Imidazole, Metronidazole & Metronidazole Benzoate. Their pharmaceutical products are sourced from the authentic vendors to assure the quality and effectiveness. The pharmaceutical products offered by the company are in compliance with IP/ BP/ CP/ USP standards. They have their registered office is located at Thane and their corporate office is located at Mumbai. Aarey Drugs & Pharmaceuticals Ltd was originally incorporated on May 15, 1990 as a private limited company in Mumbai with the name Niharika Textiles & Chemicals Pvt Ltd. The company was originally promoted by Prakash Mandhana, Kavita Mandhana and Neeta Mandhana. The company was established with the main object setting up manufacturing facilities for Bulk Drugs. In March 18, 1993, the Aarey Group of companies belonging to Ghatalia family took over the company and the company was converted into public limited company. Also, the name of the company was changed from Niharika Textiles & Chemicals Pvt Ltd to Aarey Drugs & Pharmaceuticals Ltd. In the year 1993, the company came with a public issue of 27,50,000 equity shares of Rs 10 each for cash at par aggregating to Rs 275 lakh. Also, the company shares were listed on the BSE, ASE & DSE. In May 2009, the company plant started to upgrade the existing plant into international standards. The company plans to manufacture new products Sildenafil citrate, Tinidazole & Glyxol. They plan to expand the existing production capacity of Metronidazole (MTZ) from 420 MT to 780 MT (MTZ) and Metronidazole Benzoate (MBO) from 120 MT (MBO) to 240 MT (MBO).

Read More

No Data Found

AGM Date (Month) : Sep
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 524412
Book Closure Date (Month) :
BSE Group : B
ISIN : INE198H01019

ICICIdirect Aarey Drugs & Pharmaceuticals Ltd FAQ

You can buy Aarey Drugs & Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Aarey Drugs & Pharmaceuticals Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Aug 12, 2022 04:01 PM the closing price of Aarey Drugs & Pharmaceuticals Ltd was ₹ 36.95.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Aug 12, 2022 04:01 PM, the market cap of Aarey Drugs & Pharmaceuticals Ltd stood at ₹ 93.80.
The latest PE ratio of Aarey Drugs & Pharmaceuticals Ltd as of Aug 12, 2022 04:01 PM is 14.32
The latest PB ratio of Aarey Drugs & Pharmaceuticals Ltd as of Aug 12, 2022 04:01 PM is 1.22
The 52-week high of Aarey Drugs & Pharmaceuticals Ltd is ₹ 64.40 while the 52-week low is ₹ 28.50 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote